BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer. It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.